ITP患者外周血脂质谱与促血小板生成药物疗效的相关性分析*

doi:10.3969/j.issn.1671-2587.2025.01.016

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (1): 115-120.DOI: 10.3969/j.issn.1671-2587.2025.01.016

ITP患者外周血脂质谱与促血小板生成药物疗效的相关性分析^*

周心蕙, 左斌, 王文, 何杨

苏州大学附属第一医院,江苏苏州 215000

收稿日期:2024-05-27 发布日期:2025-02-25
通讯作者: 何杨,主要从事血液学方面研究,（E-mail）heyang1963@163.com
作者简介:周心蕙,主要从事临床检验诊断学方面研究,（E-mail）2587691331@qq.com。
基金资助:
*本课题受国家自然科学基金（No. 82070123）资助

The Association between Peripheral Lipid Profile and the Efficacy of Thrombopoietic Drugs in Patients with Immune Thrombocytopenia

ZHOU Xinhui, ZUO Bin, WANG Wen, HE Yang

The First Affiliated Hospital of Soochow University, Suzhou 215000

Received:2024-05-27 Published:2025-02-25

摘要/Abstract

摘要： 目的检测免疫性血小板减少症（immune thrombocytopenia, ITP）患者外周血的脂质谱,探究脂代谢与ITP疾病的相关性。方法收集2021年1月-2023年8月于苏州大学附属第一医院血液科就诊的439例ITP患者和67例年龄与性别相匹配的健康对照者的临床资料,分析血脂生化、治疗方案、用药后血小板计数等参数与ITP疾病的相关性。根据《成人原发免疫性血小板减少症诊断与治疗中国指南》,将其中281例接受促血小板生成药物治疗的ITP患者分为有效和无效组,分析血脂水平与重组人血小板生成素（recombinant human thrombopoietin, rhTPO）/TPO受体激动剂（thrombopoietin receptor agonist, TPO-RA）疗效的相关性。结果本研究共纳入439例ITP患者和67例健康对照,ITP患者总队列和健康对照组外周血脂质水平无显著差异。281例接受rhTPO/TPO-RA治疗的ITP患者中,高甘油三酯组ITP患者rhTPO/TPO-RA治疗的起效时间更短（P=0.028 3）,血小板升高值显著高于低血脂组（P=0.003 6）。结论高甘油三酯的ITP患者促血小板生成药物疗效较好,提示外周血脂质水平可能用于预测ITP患者rhTPO/TPO-RA疗效。

关键词: 免疫性血小板减少症, 促血小板生成药物, 治疗反应, 脂质谱

Abstract: Objective To explore the correlation between lipid metabolism and ITP disease, lipid profile in peripheral blood of patients with immune thrombocytopenia (ITP) was detected and analysed , then compared with control group. Methods In this retrospective study, a total of 439 ITP patients and 67 age- and gender-matched healthy controls from the First Affiliated Hospital of Soochow University between January 2021 and August 2023 were enrolled to evaluate the association between lipid profiles and immune thrombocytopenic purpura (ITP) disease activities and response to thrombopoietic drugs. Among the ITP patients, 281 received rhTPO/TPO-RA treatment and were further categorized into responder and non-responder groups based on the Chinese guideline for adult ITP diagnosis and management. The correlation between blood lipid levels and rhTPO/TPO-RA efficacy in these patients was further investigated. Results A total of 439 ITP patients and 67 healthy controls were included in this study, but there was no significant difference in blood lipid levels between the two groups. Among 281 ITP patients who received rhTPO/TPO-RA treatment, the onset time of rhTPO/TPO-RA treatment was shorter (P=0.028 3) and the platelet count elevation was higher (P=0.003 6) in the hyperlipidemia group. Conclusion The therapeutic effect of rhTPO/TPO-RA is better in ITP patients with hyperlipidemia, suggesting that hyperlipidemia in ITP patients may serve as a predictive marker for the efficacy of rhTPO/TPO-RA treatment.

Key words: Immune thrombocytopenia, RhTPO/TPO-RA, Treatment response, Lipid profile

中图分类号:

R457

周心蕙, 左斌, 王文, 何杨. ITP患者外周血脂质谱与促血小板生成药物疗效的相关性分析^*[J]. 临床输血与检验, 2025, 27(1): 115-120.

ZHOU Xinhui, ZUO Bin, WANG Wen, HE Yang. The Association between Peripheral Lipid Profile and the Efficacy of Thrombopoietic Drugs in Patients with Immune Thrombocytopenia[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 115-120.

参考文献

[1] Neunert C,terrell DR,Arnold DM,et Al.American society of hematology 2019 guidelines for immune thrombocytopenia.blood adv.2019;3(23):3829-3866[J].Blood Adv,2020,4(2):252.
[2] KUTER D J.The structure,function,and clinical use of the thrombopoietin receptor agonist avatrombopag[J].Blood Rev,2022,53:100909.
[3] CHENG G,SALEH M N,MARCHER C,et al.Eltrombopag for management of chronic immune thrombocytopenia(RAISE):a 6-month,randomised,phase 3 study[J].Lancet,2011,377(9763):393-402.
[4] 梅恒,胡豫.成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)解读[J].临床内科杂志,2021,38(6):431-432.
[5] LAI Y F,GAO Y,LIN J H,et al.Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5[J].Cell Metab,2024,36(4):822-838.e8.
[6] XIANG W,LV H W,XING F X,et al.Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation[J].Sci Adv,2023,9(49):eadi2465.
[7] LIN H S,FU L M,LI P J,et al.Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma[J].J Transl Med,2023,21(1):343.
[8] LIU X G,HOU Y,HOU M.How we treat primary immune thrombocytopenia in adults[J].J Hematol Oncol,2023,16(1):4.
[9] Miltiadous O,Hou M,bussel JB.identifying and treating refractory ITP:difficulty in diagnosis and role of combination treatment.blood.2020;135(7):472-490[J].Blood,2020,135(25):2325.
[10] HOU Y,XIE J,WANG S W,et al.Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia[J].Cell Mol Immunol,2022,19(7):764-776.
[11] NI X F,WANG L J,WANG H Y,et al.Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia[J].Blood,2022,140(26):2818-2834.
[12] ZHANG X Y,LIU Q,LIU A L,et al.Obesity is associated with poor outcomes of corticosteroid treatment in patients with primary immune thrombocytopenia[J].Br J Haematol,2023,203(2):295-303.
[13] HAN S Q,LU H,YU Y F,et al.Hyperlipidemia in immune thrombocytopenia:a retrospective study[J].Thromb J,2023,21(1):102.
[14] OU Y,ZHAN Y X,SHAO X,et al.Lipoprotein lipids and apolipoproteins in primary immune thrombocytopenia:results from a clinical characteristics and causal relationship verification,potential drug target identification by Mendelian randomization analyses[J].Br J Haematol,2024,204(4):1483-1494.
[15] XU P C,HAN S Q,HOU M,et al.The serum lipid profiles in immune thrombocytopenia:Mendelian randomization analysis and a retrospective study[J].Thromb J,2023,21(1):107.
[16] SOBCZAK A I S,PITT S J,SMITH T K,et al.Lipidomic profiling of plasma free fatty acids in type-1 diabetes highlights specific changes in lipid metabolism[J].Biochim Biophys Acta Mol Cell Biol Lipids,2021,1866(1):158823.
[17] VALET C,BATUT A,VAUCLARD A,et al.Adipocyte fatty acid transfer supports megakaryocyte maturation[J].Cell Rep,2020,32(1):107875.
[18] BARRACHINA M N,PERNES G,BECKER I C,et al.Efficient megakaryopoiesis and platelet production require phospholipid remodeling and PUFA uptake through CD36[J].bioRxiv,2023:2023.02.12.527706.
[19] DÜRHOLZ K,SCHMID E,FRECH M,et al.Microbiota-derived propionate modulates megakaryopoiesis and platelet function[J].Front Immunol,2022,13:908174.

ITP患者外周血脂质谱与促血小板生成药物疗效的相关性分析^*

The Association between Peripheral Lipid Profile and the Efficacy of Thrombopoietic Drugs in Patients with Immune Thrombocytopenia

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	马春娅, 张敏, 付丽辉, 朱建玲, 罗圆圆, 关晓珍, 于洋. 哌拉西林钠他唑巴坦钠致药物性血小板减少症的实验室诊断研究[J]. 临床输血与检验, 2025, 27(2): 191-195.
[2]	葛洪峰, 李淑娥, 楚海亮, 杨世礼, 纪晓娟, 丰江舟, 张司琪, 邢明泉, 梁海. 沙利度胺联合二线方案治疗复发、难治性ITP患者的观察性研究^*[J]. 临床输血与检验, 2023, 25(1): 133-136.
[3]	王静, 王成云, 顾萍, 张帆, 潘秋辉. 儿童血小板抗体与自身免疫失调的相关因素分析^*[J]. 临床输血与检验, 2021, 23(6): 708-710.
[4]	马铭梓, 王秋实, 于洋. 中国人群新生儿同种免疫性血小板减少症36例文献回顾性分析^*[J]. 临床输血与检验, 2021, 23(5): 585-592.
[5]	郑静娴, 李晓辉, 孙洪强. 儿童免疫性血小板减少症的临床观察及抗核抗体在其中作用的研究[J]. 临床输血与检验, 2021, 23(2): 231-235.
[6]	黄雪原, 陈秉宇, 周明, 马现君, 陈静, 许红, 蔡丹, 胡俊, 谢毓滨, 桂嵘, 王勇军. 血小板抗体检测的多中心临床应用调查——基于中国10家单位的2 338例病例对照研究[J]. 临床输血与检验, 2020, 22(2): 113-117.
[7]	臧艳, 叶辛, 钱宝华. 原发免疫性血小板减少症患者PBMC中CD200/CD200R1表达及临床意义*[J]. 临床输血与检验, 2020, 22(1): 6-8.
[8]	刘正婷, 黄佳丽, 陈尚良. 二孩时代,我们能为FNAIT做些什么[J]. 临床输血与检验, 2019, 21(5): 552-557.
[9]	徐丹, 计成阜, 陈超, 姜金龙, 刘鑫, 王萍, 周海侠. 地塞米松联合咖啡酸片治疗ITP患者对PAIgG及GPⅡb/Ⅲa抗体的影响^*[J]. 临床输血与检验, 2019, 21(4): 368-371.
[10]	潘珂. CD80、CD86表达与ITP患者免疫紊乱的相关性研究[J]. 临床输血与检验, 2019, 21(1): 81-84.
[11]	张笑盼, 宋继军, 马曙轩. 血栓弹力图在儿童免疫性血小板减少症治疗中的应用[J]. 临床输血与检验, 2017, 19(3): 240-242.